$111.58
arrow_drop_down0.46%Key Stats | |
---|---|
Open | $111.51 |
Prev. Close | $112.10 |
EPS | -4.69 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 110.48 | 115.43 |
52 Week Range | 44.20 | 119.27 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -4.69 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
Impetigo Drugs Global Strategic Business Report 2024 - Fusidane Drug Segment is Expected to Reach US$883.5 Million by 2030, with a CAGR of a 5.1%
Vaxcyte Appoints John Furey to Board of Directors